BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022
BioStem Technologies (OTC: BSEM) was featured on Benzinga's All Access show on June 17, 2022, at 10:20 AM EST. CEO Jason Matuszewski provided updates on the company's business growth and product portfolio. BioStem Technologies focuses on perinatal tissue's regenerative properties, utilizing the proprietary BioRetain® processing method to enhance growth factors and tissue structure. The company's manufacturing is FDA registered and AATB accredited, with products like VENDAJE® at its Pompano Beach, Florida site.
- CEO provides business growth updates, highlighting potential for investor interest.
- The proprietary BioRetain® processing method enhances product efficacy, appealing to the regenerative medicine market.
- FDA registered and AATB accredited manufacturing indicates high-quality and safety standards.
- None.
POMPANO BEACH, FLORIDA, June 17, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies® (OTC: BSEM), a leading, innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies will be hosted on Benzinga’s All Access show, which airs on Benzinga TV and Benzinga’s YouTube channel on June 17 2022, at 10:20 AM EST.
BioStem Technologies CEO Jason Matuszewski will be interviewed and provide updates on the latest developments in BioStem’s business growth and portfolio of products. A link to the YouTube broadcast will be available in our investor relations news portal at the below link:
https://www.biostemtechnologies.com/news.
Or watch or listen live to the All-Access broadcast via the Benzinga YouTube channel in the link below:
https://www.youtube.com/watch?v=e86eV1JzMontserratDzo
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain® processing method. BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB®”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes VENDAJE®, VENDAJE® AC, and VENDAJE® OPTIC. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
Investor Relations:
info@biostemtech.com
(954) 380-8342
FAQ
When did BioStem Technologies appear on Benzinga's All Access show?
What updates were provided by BioStem Technologies CEO Jason Matuszewski?
What is the focus of BioStem Technologies?
